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Background-—The majority of coronary bifurcation lesions are treated with a provisional single-stent strategy rather than an up-
front 2-stent strategy. This approach is supported by multiple randomized controlled clinical trials with short- to medium-term
follow-up; however, long-term follow-up data is evolving from many data sets.
Methods and Results-—Meta-analysis of randomized controlled trials evaluating long-term outcomes (≥1 year) according to
treatment strategy for coronary bifurcation lesions. Nine randomized controlled trials with 3265 patients reported long-term
clinical outcomes at mean weighted follow-up of 3.11.8 years. Provisional single stenting was associated with lower all-cause
mortality (2.94% versus 4.23%; risk ratio: 0.69; 95% conﬁdence interval, 0.48–1.00; P=0.049; I2=0). There was no difference in
major adverse cardiac events (15.8% versus 15.4%; P=0.79), myocardial infarction (4.8% versus 5.5%; P=0.51), target lesion
revascularization (9.3% versus 7.6%; P=0.19), or stent thrombosis (1.8% versus 1.6%; P=0.28) between the groups. Prespeciﬁed
sensitivity analysis of long-term mortality at a mean of 4.7 years of follow-up showed that the provisional single-stent strategy was
associated with reduced all-cause mortality (3.9% versus 6.2%; risk ratio: 0.63; 95% conﬁdence interval, 0.42–0.97; P=0.036; I2=0).
Conclusions-—Coronary bifurcation percutaneous coronary intervention using a provisional single-stent strategy is associated with
a reduction in all-cause mortality at long-term follow-up. ( J Am Heart Assoc. 2018;7:e008730. DOI: 10.1161/JAHA.118.
008730.)
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B ifurcation lesions are common and account for up to oneﬁfth of percutaneous coronary interventions. Typically,
they are deﬁned as a lesion at or near a signiﬁcant division of a
major epicardial artery into 2 branches (main vessel [MV] and
side branch [SB]).1 This patient group merits special attention
because of the high burden of adverse events following
treatment.2 Many clinical trials have compared a single-stent
strategy (MV only with a provisional approach to SB stenting)
with an up-front 2-stent strategy. At short-term follow-up,
randomized controlled trials (RCTs) show overall similar
efﬁcacy between the 2 approaches; however, a provisional
single-stent strategy (with bailout use of a second stent)
demonstrates improved safety and lower costs.3 Recent data
emerging from Asia support the double-kissing (DK) crush 2-
stent technique over provisional stenting, refueling the debate
about the optimal treatment of these lesions.4,5
A short-term focus on these patients will miss detection of
important late complications (>1 year) after bifurcation
percutaneous coronary intervention including death, myocar-
dial infarction (MI), stent thrombosis (ST), and target lesion
revascularization (TLR). These important events may accrue
particularly as the protective effect of dual antiplatelet
therapy (DAPT) is withdrawn, unmasking sequelae of under-
expanded stents and malapposed struts. The frequency of
these outcomes may vary in the longer term, according to
treatment strategy. Consequently, we performed a meta-
analysis of RCTs comparing the long-term clinical outcomes of
1- and 2-stent strategies for treating coronary bifurcation
lesions.
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Method
The data, analytic methods, and study materials have been
made available to other researchers for the purposes of
reproducing the results or replicating the procedure. The full
study protocol was registered with the PROSPERO interna-
tional database of prospectively registered systematic reviews
in health and social care (CRD42017081091). This study was
performed following the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) guidelines.6
Eligibility Criteria
The inclusion criteria for studies were as follows: clinical RCTs
comparing provisional versus up-front 2-stent strategies for
bifurcation lesions regardless of the speciﬁc stenting technique
and SB size and lesion complexity. Publications were excluded if
they compared various 2-stent techniques without a provisional
stenting arm, utilized a dedicated bifurcation stent or included
non–coronary bifurcation lesions. Nonrandomized trials, pub-
lications not in English, and those without clinical outcomes of
interest during at least 1 year of follow-up were all excluded.
Quality Assessment
Risk of bias and quality assessment of the included trials was
independently performed by 2 reviewers (T.F. and P.M.)
Discrepancies were resolved by consensus with a third
independent reviewer (D.C.). Quality assessment according to
the Cochrane Collaboration framework is provided (Fig-
ure 1).7 Publication bias was assessed according to funnel
plot asymmetry using standard error as the measure of study
size and risk ratio of treatment effect.8
Search Strategy
A systematic search of the online databases PubMed,
Cochrane Central Register of Controlled Trials (CENTRAL),
EBSCO (Medline), and Web of Science was performed through
November 11, 2017. Peer-reviewed RCTs were selected using
combinations of the keywords bifurcation, coronary, outcomes
and provisional. Two reviewers (T.F. and P.M.) independently
screened abstracts against inclusion and exclusion criteria,
and reference lists of relevant articles and meta-analyses
were reviewed for other relevant studies. Conference
abstracts from recent major cardiology meetings were
searched for completeness, including EuroPCR, the European
Society of Cardiology, the American College of Cardiology, the
American Heart Association, and Transcatheter Cardiovascu-
lar Therapeutics.
Outcomes and Deﬁnitions
The primary outcome was all-cause mortality. Secondary
outcomes included MI, deﬁnite or probable ST, TLR, and major
adverse cardiac events (MACE). Outcome data were extracted
by 2 independent authors (T.F and D.C.). Differences in
opinion were resolved by consensus involving a third reviewer
Figure 1. Risk of bias summary—Cochrane risk tool.
Clinical Perspective
What Is New?
• This large meta-analysis of randomized controlled trials of
bifurcation coronary stent strategies supports a provisional
single-stent strategy over upfront 2-stent strategy.
What Are the Clinical Implications?
• Coronary bifurcation angioplasty may be performed safely
using a provisional single-stent approach.
• This simpler option, as appropriate, may reduce fatal long-
term sequelae associated with complex 2-stent bifurcation
strategies.
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(P.M.). Probable or deﬁnite ST was determined according to
the Academic Research Consortium deﬁnition.9 MACE was
deﬁned as the composite of death, MI, and target vessel
revascularization (TVR). Minor variations in end point deﬁni-
tions of MI, MACE, and TLR within the clinical trials are
reported in Table 1.
Statistical Analysis
Weighted mean follow-up duration was calculated according
to study size. Pooled mean data were used to compare
procedural aspects between the groups using an unpaired t
test. All major study hypotheses were prespeciﬁed and tested
on an intention-to-treat basis with a 2-tailed a of 0.05.
The random-effects method was selected because of the
various studies estimating different yet related intervention
effects related to different types of 2-stent techniques and
lesions enrolled. We also performed a ﬁxed-effect (Mantel–
Haenszel) approach for completeness. We summarize the
estimate of effect incorporating the clinical outcomes as the
risk ratio (RR) with 95% conﬁdence intervals (CIs). Hetero-
geneity testing was performed with Higgins I2 and a
threshold of >50% suggestive of signiﬁcant heterogeneity
between studies.19 Given that the expected number of
events was anticipated to be small, typically used large
sample approximations were anticipated to be less reliable.
Exact probability assessment with the Fisher exact test was
thus also performed. A prespeciﬁed sensitivity analysis was
performed of studies reporting >3 years of outcome data to
determine more information on long-term outcomes. Statis-
tical analysis was performed using STATA software v13 and
RevMan v5. We also performed an explorative metaregres-
sion analysis to assess the effect of selected variables (acute
coronary syndrome, minimum duration of DAPT, left main
bifurcation, ﬁnal kissing balloon inﬂation, and stent genera-
tion [ﬁrst- or second-generation drug-eluting stent]) on all-
cause mortality.
Results
Our initial search yielded 278 studies. Nine randomized trials
met the inclusion criteria, reporting mortality at ≥1 year of
follow-up.4,5,10,11,13–18
A total of 3265 patients were enrolled with weighted mean
follow-up of 3.11.8 years. The total loss to follow-up of
patients in the study was <1%. In total, 1633 were randomized
to an initial single-stent strategy and 1632 were randomized
to a 2-stent strategy. The mean age of the population was
63.41.4 years. Overall, 59.9% of the procedures were
performed in patients with stable coronary artery disease,
whereas 40.1% underwent percutaneous coronary
intervention for acute coronary syndrome. Patient demo-
graphics are listed in Table 1.
The use of a single-stent strategy was associated with
shorter procedural time (52.212.5 versus 64.017.0 min-
utes; P<0.001) and less volume of contrast used (227.668.7
versus 250.766.3 mL; P<0.001). Crossover to 2 stents in the
single-stent group occurred in 17.9% of lesions treated.
Crossover to a single stent in the 2-stent group occurred in
7.6% of lesions. Further procedural details are listed in Table 2.
Compared with 2-stent techniques, the provisional single-
stent approach was associated with lower all-cause mortality
(2.94% versus 4.23%; RR=0.69; 95% CI, 0.48–1.00; 2-sided
Fisher exact test, P=0.049; I2=0%; Figures 2 and 3). The
absolute risk difference in mortality was 1.29% lower with a
provisional single-stent technique (95% CI, 0.01–2.56%; 2-
sided Fisher exact test, P=0.049). An alternative ﬁxed-effects
analysis provided similar results (2.94% versus 4.23%;
RR=0.69; 95% CI, 0.48–0.99; P=0.04).
There was no difference in MACE (15.8% versus 15.4%;
RR=1.04; 95% CI, 0.76–1.43; P=0.79; I2=66%) or MI (4.8%
versus 5.5%; RR=0.85; 95% CI, 0.52–1.38; P=0.51; I2=37%)
between the allocated treatment groups. These secondary
end points at ≥12 months of follow-up were reported for 8 of
the 9 RCTs in the analysis. Further secondary end points are
plotted in Figure 4, conﬁrming no difference in TLR (9.3%
versus 7.6%; RR=1.25; 95% CI, 0.89–1.75; P=0.19; I2=39%) or
ST (1.8% versus 1.6%; RR=0.98; 95% CI, 0.38–1.99; P=0.28;
I2=19%).
A prespeciﬁed sensitivity analysis was carried out to
investigate only trials with ≥3 years of follow-up. Five studies
were included, with a total of 1713 patients followed up for an
average of 4.7 years.4,10,12,15,18 Compared with an up-front 2-
stent technique, stenting the MV only was associated with a
lower risk of all-cause mortality (3.9% versus 6.2%; RR 0.63;
95% CI, 0.42–0.97; P=0.036; I2=0%) with a trend toward a
reduction in MI (2.4% versus 4.7%; RR=0.56; 95% CI, 0.3–
1.04; P=0.06; I2=0%). There were no signiﬁcant differences in
long-term TLR or ST. Figure 3 provides the main outcomes of
interest in the study. Metaregression analysis did not show
any signiﬁcant relationship between primary outcome effect
size and selected clinical variables (eg, ﬁnal kissing balloon
inﬂation, proportion of ﬁrst-generation drug-eluting stent use,
or left main coronary bifurcation location). A summary of this
study is shown in the central illustration (Figure 5).
Discussion
In the largest meta-analysis of randomized trials comparing
treatment strategies for coronary bifurcation lesions, we have
shown reduced all-cause mortality at medium- to long-term
follow-up in patients randomly assigned to an initial strategy
of MV stenting only compared with up-front stenting of both
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the MV and SB. There was a 31% relative risk reduction in
death at mean weighted follow-up of 3.1 years, extending to
an overall 37% relative risk reduction at mean 4.7 years of
follow-up. The provisional single-stent “less is more” approach
is attractive and clinically impactful because of simplicity
without compromising long-term outcomes. Overall, long-term
all-cause mortality is low throughout the studies. We included
in our analysis the patient-level 5-year data from the Nordic
bifurcation study and BBC1 (British Bifurcation Coronary
Study) in which reduced mortality with the single-stent
approach was previously reported.15 It is plausible that the
use of ﬁrst-generation drug-eluting stents in these 2 studies
led to increased events in the 2-stent cohorts compared with
later trials using more contemporary devices.
Notably, we did not ﬁnd a difference in MACE, MI, TLR, or
ST; therefore, the reason for the increased death rate is not
immediately apparent. There are several reasons why this
might be seen. One limiting assumption is that the differential
mortality rates most likely reﬂect increased cardiac death
from STs. Most studies considered all-cause mortality rather
than speciﬁc cardiac mortality. Another potentially relevant
mode of all-cause death in the 2-stent group relates to
bleeding episodes, which would vary according to the duration
of DAPT. Physicians treating patients in these open-label trials
may preferentially keep the 2-stent group on prolonged DAPT
with inherent risks of bleeding related morbidity, and mortality
in the long term. Indeed, a large meta-analysis of RCTs
showed increased all-cause mortality in patients randomized
to extended DAPT (odds ratio: 1.30; 95% CI, 1.02–1.66;
P=0.03).20 Bleeding events and duration of DAPT were not
uniformly reported, so the precise cause of mortality is
unclear. Although all-cause mortality reduction can be a
challenging primary end point to meet for an individual RCT, it
has some theoretical advantages when used in a meta-
analysis with long-term follow-up. It is a binary outcome that
is easy to determine and of utmost clinical important to
patients, trial designers, and funders. All-cause mortality is a
robust measure, particularly given declining rates of non-
forensic autopsy—sudden death in elderly patients is not
usually investigated with a postmortem.21 Academic Research
Consortium criteria for acute ST may not be met despite
autopsy-proven ST. This suggests that ST is likely to be
substantially underreported.22 Including all-cause mortality
improves the power to detect these important events and is
the most reliably obtained clinical outcome at long-term
follow-up.
Data from nonrandomized trials also support the more
conservative approach of MV stenting only.23 Our work builds
on a previous meta-analysis24 by incorporating 2 recent
seminal publications with long-term follow-up supporting the
DK crush 2-stent bifurcation technique.4,5 Despite the inclu-
sion of these data sets, the provisional stent strategy still
appears to be associated with a reduced mortality at medium-
to long-term follow-up.
After 5 years of follow-up in the DK Crush II (Double
Kissing Crush versus Provisional Stenting Technique for
Treatment of Coronary Bifurcation Lesions) trial, patients
treated with the 2-stent strategy had improved outcomes
compared with MV-only stenting. This effect was largely
driven by reduced TLR. After 1 year of follow-up in the DK
Crush V (Double Kissing and Double Crush Versus Provisional
T Stenting Technique for the Treatment of Unpro- tected
Distal Left Main True Bifurcation Lesions: A Randomized,
International, Multi-Center Clinical Trial) study, patients with
left main bifurcation lesions treated with the 2-stent strategy
had a reduction in MACE, ST, and TLR compared with MV
stenting only. DK Crush V was the only study to exclusively
enroll patients with left main lesions—these patients had
complex and extensive SB involvement (mean diameter
stenosis 66%, lesion length 30 mm). Many operators would
not feel comfortable adopting a provisional strategy for such
complex disease involving a large SB. It is important to
acknowledge that the DK crush technique is not simple, and
the trial ﬁndings may not be generalizable to the typical
Figure 2. Forest plot of primary outcome: all-cause mortality according to bifurcation treatment strategy. Nordic 2013,10 BBK,11,12
PERFECT,13 Nordic-Baltic Bifurcation IV,14 BBC1,15,16 EBC2,17 Smart-Strategy,18 DK Crush II 2017,4 DK Crush V.5 CI indicates conﬁdence
interval; M-H, Mantel-Haenszel test.
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interventional cardiologist. In DK Crush V, operators had to
perform at least 300 percutaneous coronary interventions per
year for 5 consecutive years to recruit patients into the study.
In addition, they had to demonstrate proﬁciency
of the technique by submitting 5 exemplary cases of DK
crush to the investigators before taking part. Importantly, the
DK crush studies may account for the heterogeneity observed
in secondary end points in the meta-analysis. Differences
between these and other studies include more patients with
acute coronary syndrome (pooled mean: 83.4% versus 30.7%)
and left main coronary disease (63.8% versus 5.2%), as well as
more frequent stenting of the SB in the provisional stent
Figure 3. A, All-cause mortality according to bifurcation treatment strategy. 3265 patients were enrolled
in 9 randomized trials with weighted mean follow-up of 3.1 years. The total loss to follow-up of patients in the
study was < 1%. Nordic 2013,10 BBK,11,12 PERFECT,13 Nordic-Baltic Bifurcation IV,14 BBC1,15,16 EBC2,17
Smart-Strategy,18 DK Crush II 2017,4 DK Crush V.5 B, Long-term health outcomes of provisional stenting vs a
complex strategy for treatment of coronary bifurcation lesions. *Long-term mortality incorporating trials with
≥3 years of clinical follow-up: A prespeciﬁed sensitivity analysis was carried out of ﬁve studies including
1713 patients followed up for an average of 4.7 years. DK CrushII,4 Nordic,10 BBK,12 BBC1,15 Smart-
Strategy.18 CI indicates conﬁdence interval; MACE, major adverse cardiac events; MI, myocardial infarction;
RRR, relative risk reduction with provisional vs 2-stent strategies; TLR, target lesion revascularization.
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A - MACE
B - MI
C - TLR
D - ST
Figure 4. Forest plots for secondary end points. A, Major adverse cardiac events (MACE). B, Myocardial infarction (MI).
C, Target lesion revascularization (TLR). D, Stent thrombosis (ST).
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group (39.2% versus 10.6%). Furthermore, there was
increased use of ﬁnal kissing balloons in the single-stent
arm (79.0% versus 50.3%). The high crossover to 2 stents in
the patients randomized to single stent may reﬂect an
increased complexity of bifurcation disease in the DK crush
trials and may explain the surprisingly high rate of ST in the
provisional arm of DK Crush V (3.3% versus 0.4%; P=0.02).
Limitations
A signiﬁcant proportion of trials in our analysis used ﬁrst-
generation drug-eluting stents (n=4). These stents have a
known higher and continuous risk of ST for over 5 years and
may have driven excess mortality in the up-front 2-stent
group.25 Metaregression incorporating the percentage of ﬁrst-
generation drug-eluting stents in each trial did not show a
statistically signiﬁcant interaction with effect size. Neverthe-
less, our conclusions may not be generalizable to contempo-
rary practice using newer generation drug-eluting stents.
Despite the prespeciﬁed nature of our sensitivity analysis,
many secondary analyses were performed at the 5% level of
signiﬁcance without any adjustments for multiple testing.
Furthermore, Higgins I2 suggested signiﬁcant heterogeneity of
secondary outcome measures in the meta-analysis. Method-
ology, demographics, and deﬁnitions of MI, MACE, and TLR
varied between studies and may account for some of this
(Table 1). Differences in bifurcation lesion complexity,
anatomical location, 2-stent techniques, procedural details,
stent types, and intensity of DAPT are all likely to be present
but could not be fully accounted for (Table 2). Most trials had
follow-up coronary angiography mandated in the protocol. This
was done typically 8 to 9 months after the index procedure,
occurring before the adjudication of 12-month outcomes
including target vessel revascularization. The oculostenotic
reﬂex and related revascularization is a known pitfall of routine
angiographic follow-up and may have driven events in this
study.26 Individual patient-level data were not available but
would have been helpful to probe these factors. We included
the SMART-STRATEGY trial (optimal strategy for SB stenting in
coronary bifurcation lesion) although the rate of SB stenting in
the 2-stent arm was <50%. The ongoing EBC main trial aims to
determine whether the approach of stenting the MV only is
safe and effective in the contemporary treatment of true left
main bifurcation lesions.27 Although our study supports the
simplicity of a provisional single-stent approach, operators
may reasonably opt for an up-front 2-stent strategy in patients
with complex bifurcation lesions with extensive involvement of
a large SB (particularly left main disease).
Conclusion
Despite recent studies supporting a default 2-stent strategy
for treatment of coronary bifurcation lesions, no one size ﬁts
all. Our meta-analysis supports the provisional single-stent
strategy as the default approach for treatment of coronary
bifurcation lesions.
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Figure 5. Central illustration (graphic summary of study). f/u indicates follow-up; PCI, percutaneous
coronary intervention; RCTs, randomized controlled trials; RRR, relative risk ratio. *Denotes P=0.049
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